FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, and concerns using a human Annexin-1 antibody (Anx-A1), which has the sequence SEQ ID NO: 23 for treating a disease caused by abnormal T-cell activation. The group of inventions also concerns a method of treating a disease caused by abnormal T-cell activation, involving administering a therapeutic amount of the above antibody into an individual in need thereof; using the above antibody for producing a therapeutic agent for treating a disease caused by abnormal T-cell activation.
EFFECT: group of inventions provides treating the disease caused by abnormal T-cell activation.
9 cl, 11 ex, 22 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-HUMAN ANNEXIN A1 ANTIBODY | 2011 |
|
RU2596403C2 |
| COMPOSITIONS FOR TREATMENT OF DISSEMINATED SCLEROSIS | 2008 |
|
RU2492234C2 |
| PHARMACEUTICAL COMPOSITION FOR IMMUNE DISEASE TREATMENT | 2000 |
|
RU2203682C2 |
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
| NEW SUBPOPULATION OF TREG CD8CD45RC CELLS AND ITS APPLICATIONS | 2016 |
|
RU2766691C2 |
| METHOD TO DIAGNOSE ALLERGIC REACTIONS | 2009 |
|
RU2536291C2 |
| RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
| ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND APPLICATION THEREOF | 2015 |
|
RU2661678C1 |
| ALLERGIC SENSITISATION PREVENTION | 2008 |
|
RU2429881C2 |
| LABELED CHIMERIC EFFECTOR MOLECULES AND RECEPTORS THEREOF | 2014 |
|
RU2729463C2 |
